We can't find the internet
Attempting to reconnect
14785.1 PFLS-LS
14785.1 PFLS-LS
Résumé
Characterization and optimization of a novel drug class based on allosteric modulation for applications in neurodegenerative and psychiatric disorders
Textes supplémentaires
Abstract
The objective of this project is the characterization and optimization of a new class of drug candidates based on allosteric modulation for neurodegenerative and psychiatric diseases. Specifically, allosteric modulators targeting Group III of metabotropic glutamate receptors will be assessed in animal models replicating human Parkinson‟s disease (mGluR4), whereas electrophysiological studies will be carried out on allosteric modulators targeting mGluR4 and mGluR7, in order to investigate their role in modulating synaptic transmission and further characterize their potential therapeutic application in neurodegenerative diseases and anxiolytic disorders. Project results will contribute in the selection of the best candidate compounds for clinical development.
Participants
Graham Dixon
Wirtschaftspartner
graham.dixon@addextherapeutics.com
Addex Pharmaceuticals SA Graham Dixon Chemin des Aulx 12 1228 Plan-les-Ouates GE CH
Ron Stoop
Kontaktperson
Ron.Stoop@unil.ch
CHUV Centre Hospitalier Universitaire Va Centre for Psychiatric Neuroscience Ron Stoop Hôpital de Cery / Route de Cery 1005 Lausanne VD CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2013-05-31
- Date de fin
- 2015-11-30
- Coûts totaux approuvés
- CHF 708030.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T490 Biotechnology 100.0%